Ozempic has emerged as a significant player in the management of type 2 diabetes and, more recently, in the realm of weight loss
Multiple studies have shown people regaining weight after stopping GLP-1 medications
They encapsulate sensitive ingredients like glutathione as protective carriers
A substantial body of evidence from animal studies [92,93,94,95] and clinical trials [96,97,98,99,100,101] indicates that GLP-1 RAs have a marked effect in ameliorating myocardial ischemia, reducing reperfusion injury, decreasing infarct size, and enhancing cardiac function
Several studies have shown that complete withdrawal of an obesity treatment dose of a GLP-1RA without other structured care leads to weight regain in most people.2 However, it remains unclear whether lifelong treatment of obesity should always consist of GLP-1RAs at full obesity dosing or whether a range of alternative strategies can enable some subset of people with obesity to maintain their weight loss after a limited duration of initial treatment, followed by tapering, discontinuing, or off-ramping these agents." This paragraph from the article, I believe, sums up nicely what this means
This is a known effect of glucagon receptor activation and is being monitored closely
